Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Journal of Pathology and Translational Medicine. 2017;51(4):441-443 
Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Clinical Lung Cancer. 2015;16(3):228-236
Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach
Cytopathology. 2020;31(3):232-235
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma
Internal Medicine Journal. 2012;42(11):1269-1270
E-29. Epidermal growth factor receptor tyrosine kinase inhibitors: Single agent therapy
Lung Cancer. 2003;41:S38
Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2004;6:S20-S23
THE EGFR
MUTATION PATTERN AFTER EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER HARBOURING ACTIVATING UNCOMMON EGFR
MUTATIONS
Respirology. 2018;23:286-286
Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis
Thoracic Cancer. 2011;2(3):101-108
Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Carcinoma
Clinical Lung Cancer. 2006;8:S31-S35
FEASIBILITY AND CLINICAL IMPACT OF RE-BIOPSY IN ADVANCED LUNG ADENOCARCINOMA AFTER PROGRESSES DURING FIRST-LINE EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS
Respirology. 2018;23:9-9